ChemoCentryx Inc (OQ:CCXI)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 850 Maude Ave
Tel: 1-650-2102900
IR: See website
Key People
Thomas J. Schall
Chairman of the Board, President, Chief Executive Officer
Susan M. Kanaya
Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary, IR Contact Officer
Rajinder Singh
Senior Vice President - Research
Markus J. Cappel
Chief Business Officer, Treasurer
Business Overview
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Financial Overview
For the fiscal year ended 31 December 2019, ChemoCentryx Inc revenues decreased 16% to $36.1M. Net loss increased 46% to $55.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expense increase of 12% to $70.3M (expense), General and administrative increase of 18% to $24.2M (expense).
Employees: 82 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $2,288M as of Dec 31, 2019
Annual revenue (TTM): $36.13M as of Dec 31, 2019
EBITDA (TTM): -$56.66M as of Dec 31, 2019
Net annual income (TTM): -$55.49M as of Dec 31, 2019
Free cash flow (TTM): -$70.91M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 61,644,571 as of Feb 28, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization